Literature DB >> 28234587

Analysis of contributing factors influencing thromboembolic events after total knee arthroplasty.

Sylvie Plante1, Etienne L Belzile1, Dominique Fréchette1, Jean Lefebvre1.   

Abstract

BACKGROUND: Venous thromboembolic events (VTE) are a known and well-described complication following total knee arthroplasty (TKA). We sought to validate the American College of Chest Physicians thromboprophylaxis recommendations after elective TKA, paying special attention to our dose adjustments for weight, and their impact on VTE in our population.
METHODS: We retrospectively investigated risk factors in patients undergoing TKA, focusing mainly on symptomatic VTE occurrence rates from deep vein thrombosis (DVT) or pulmonary embolism (PE). The anticoagulation protocol consisted of starting low molecular-weight heparin (LMWH) therapy, with dalteparin administered 12 h after surgery in patients who received general anesthesia or 24 h later in patients who received single-dose regional anesthesia.
RESULTS: Data from 346 patients (mean age 66.8 [range 24-91] yr) who underwent primary or revision TKA depicted an overall symptomatic VTE rate of 15%. The proximal DVT rate was 1.7%, and the nonfatal PE rate was 0.9%. The mean time to VTE diagnosis was 5.6 days. The first dalteparin dose was administered 19.5 (range 10-48) h after surgery in patients without VTE and 22.6 (range 11.5-52) h after surgery in patients with VTE (p = 0.003). With a first dose of dalteparin administered 12 h postoperatively, patients presented significantly lower DVT and PE rates than if it was administered 24 h postoperatively (8.5% v. 16.3%, p = 0.048).
CONCLUSION: Delayed administration of LMWH has deleteriously impacted the VTE rate after TKA at our institution. Prompt initiation of LMWH (≤ 12 h after surgery) is appropriate, without increasing the risk of major bleeding.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28234587      PMCID: PMC5373740          DOI: 10.1503/cjs.008216

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  21 in total

1.  Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial.

Authors:  Nils Kucher; Alain Leizorovicz; Paul T Vaitkus; Alexander T Cohen; Alexander G G Turpie; Carl-Gustav Olsson; Samuel Z Goldhaber
Journal:  Arch Intern Med       Date:  2005-02-14

2.  Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis.

Authors:  Renée L Schiff; Susan R Kahn; Ian Shrier; Carla Strulovitch; Wahbi Hammouda; Eva Cohen; David Zukor
Journal:  Chest       Date:  2005-11       Impact factor: 9.410

3.  The prevalence of venous thromboembolism after hip and knee replacement surgery.

Authors:  Richard F O'Reilly; Ian A Burgess; Bernard Zicat
Journal:  Med J Aust       Date:  2005-02-21       Impact factor: 7.738

4.  The incidence of thromboembolic events in surgically treated ankle fracture.

Authors:  Stéphane Pelet; Marie-Eve Roger; Etienne L Belzile; Marc Bouchard
Journal:  J Bone Joint Surg Am       Date:  2012-03-21       Impact factor: 5.284

5.  Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition).

Authors:  Terese T Horlocker; Denise J Wedel; John C Rowlingson; F Kayser Enneking; Sandra L Kopp; Honorio T Benzon; David L Brown; John A Heit; Michael F Mulroy; Richard W Rosenquist; Michael Tryba; Chun-Su Yuan
Journal:  Reg Anesth Pain Med       Date:  2010 Jan-Feb       Impact factor: 6.288

6.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 7.  American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients?

Authors:  John W Eikelboom; Ganesan Karthikeyan; Nick Fagel; Jack Hirsh
Journal:  Chest       Date:  2009-02       Impact factor: 9.410

8.  High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxis.

Authors:  Jason Kerr; Lori-Ann Linkins
Journal:  Thromb Haemost       Date:  2009-10-26       Impact factor: 5.249

9.  Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery.

Authors:  D J Quinlan; J W Eikelboom; O E Dahl; B I Eriksson; P S Sidhu; J Hirsh
Journal:  J Thromb Haemost       Date:  2007-04-07       Impact factor: 5.824

10.  Low risk of thromboembolic complications after fast-track hip and knee arthroplasty.

Authors:  Henrik Husted; Kristian Stahl Otte; Billy B Kristensen; Thue Ørsnes; Christian Wong; Henrik Kehlet
Journal:  Acta Orthop       Date:  2010-10       Impact factor: 3.717

View more
  2 in total

1.  Thirty-day Postoperative Complications following Primary Total Knee Arthroplasty: A Retrospective Study of Incidence and Risk Factors at a Single Center in China.

Authors:  Bin Feng; Jin Lin; Jin Jin; Wen-Wei Qian; Wei Wang; Xi-Sheng Weng
Journal:  Chin Med J (Engl)       Date:  2017-11-05       Impact factor: 2.628

2.  Preferences and Practices of Brazilian Orthopedists for Thromboprophylaxis Techniques in Total Knee Arthroplasty: Survey Among Members of the Brazilian Society of Knee Surgery (SBCJ).

Authors:  João Alberto Ramos Maradei-Pereira; Mateus Costa Barbosa; Derek Frederick Silva Newbery; Marcelo Rodrigues Torres; André Kuhn; Marco Kawamura Demange
Journal:  Rev Bras Ortop (Sao Paulo)       Date:  2022-08-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.